Arunachalam Gnanapragasam, Upadhyay Rohit, Ding Hong, Triggle Chris R
Departments of *Pharmacology; and †Medical Education, Weill Cornell Medical College in Qatar, Doha, Qatar.
J Cardiovasc Pharmacol. 2015 May;65(5):419-29. doi: 10.1097/FJC.0000000000000178.
The worldwide increase in the prevalence of obesity and type 2 diabetes and the associated elevated risk of cardiovascular disease (CVD) has emphasized the need to seek new therapeutic targets to offset the negative impact on human health outcomes. In this regards, microRNAs (miRNAs), a class of small noncoding RNAs that mediate posttranscriptional gene silencing, have received considerable interest. miRNAs repress gene expression by their ability to pair with target sequences in the 3' untranslated region of the messenger RNA. miRNAs play a crucial role in the biogenesis and function of the cardiovascular system and are implicated as dynamic regulators of cardiac and vascular signaling and pathophysiology. Numerous miRNAs have been identified as novel biomarkers and potential therapeutic targets for CVD. In this review, we discuss the contribution of miRNAs to the regulation of CVD, their role in macrovascular/microvascular (dys)function, their potential as important biomarkers for the early detection of CVD, and, finally, as therapeutic targets.
全球范围内肥胖症和2型糖尿病患病率的上升以及心血管疾病(CVD)相关风险的增加,凸显了寻找新治疗靶点以抵消对人类健康结果负面影响的必要性。在这方面,微小RNA(miRNA)作为一类介导转录后基因沉默的小非编码RNA,受到了广泛关注。miRNA通过与信使RNA 3'非翻译区的靶序列配对来抑制基因表达。miRNA在心血管系统的生物发生和功能中起着关键作用,并被认为是心脏和血管信号传导及病理生理学的动态调节因子。众多miRNA已被确定为CVD的新型生物标志物和潜在治疗靶点。在本综述中,我们讨论了miRNA对CVD调节的贡献、它们在大血管/微血管(功能障碍)中的作用、它们作为CVD早期检测重要生物标志物的潜力,以及最终作为治疗靶点的潜力。